Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geovax LabsGOVX -14.16%22 EPS without NRI is $-21.67 as of Mar. 2026. GuruFocus rates GOVX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,168 Biotechnology companies, Geovax Labs ranks better than 88.61% on this metric.
Geovax Labs's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-2.62.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.67.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 58.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 50.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Geovax Labs's EPS without NRI or its related term are showing as below:
GOVX'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 23.6 Med: 58.3 Max: 82.8
Current: 58.3
During the past 13 years, Geovax Labs's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 82.80% per year. The lowest was 23.60% per year. And the median was 58.30% per year.
GOVX's 3-Year EPS without NRI Growth Rate is ranked better than 88.61% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs GOVX: 58.30
Geovax Labs's EPS (Diluted) for the
three
months ended in Mar. 2026 was $-2.62.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.67.
Geovax Labs's EPS (Basic) for the
three
months ended in Mar. 2026 was $-2.62.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.67.
Geovax Labs (NAS:GOVX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Geovax Labs EPS without NRI Related Terms
Geovax Labs EPS without NRI Historical Data
* Premium members only.
The historical data trend for Geovax Labs's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GOVX vs XBIO, MTVA, ACXP: EPS without NRI Comparison
For the Biotechnology subindustry, Geovax Labs's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Geovax Labs's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geovax Labs (GOVX) has a EPS without NRI of $-21.67 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Geovax Labs and its competitors. According to the industry distribution chart, Geovax Labs ranks #133 out of 1168 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Geovax Labs' EPS without NRI too high?
Geovax Labs' current EPS without NRI is $-21.67. Based on the distribution chart, Geovax Labs ranks #133 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geovax Labs has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' EPS without NRI compare to XBIO and MTVA?
According to the Biotechnology industry distribution chart, Geovax Labs ranks #133 out of 1168 companies for EPS without NRI. This places Geovax Labs in the top 11% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Geovax Labs and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geovax Labs's current EPS without NRI is $-21.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current EPS without NRI of $-21.67. The current EPS without NRI is $-21.67. Geovax Labs' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Geovax Labs (GOVX), the current EPS without NRI is $-21.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score
Get the complete analysis for GOVX
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOVX has been successfully added to your 
